BluMaiden unites deep scientific and technological expertise with proven industry leadership in clinical drug development — combining a world-class TechBio core with seasoned pharmaceutical innovators to accelerate the translation of discovery into impact.
Chair of the Scientific Advisory Board Member, and Board of Directors Member
Chair of the Scientific Advisory Board Member, and Board of Directors Member
Chair of the Scientific Advisory Board Member, and Board of Directors Member
Translating (meta)genomic dark matter into predicted chemical structures to drive discovery.
Predict, prioritize, and optimize nature-derived scaffolds and their derivatives from biosynthetic diversity.
Custom ML architectures and data pipelines delivering clinically relevant diagnostic and prognostic models.
Integrative analysis to reveal targets, mechanisms, and new biology not visible in single-omic views.
Unified data, models, and workflows – standardized, version-controlled, and built to scale programs reproducibly.
At BluMaiden, we harness the power of AI to unlock the therapeutic potential of human-derived natural products – molecules shaped by nature and refined by evolution. Our platform combines three integrated analytical engines, each designed to explore distinct layers of biological and chemical data, transforming an underexplored chemical universe into actionable insights for modern drug discovery. By combining deep neural networks, biology-inspired genomic representations, and custom molecular models that capture ligand-target interactions, we translate complex biological information into pathways for safe and effective therapeutics.
This innovation is driven by a world-class team. Oleg Moskvin, Ph.D., Head of AI & Computational Discovery, leads our AI and computational efforts via inter-domain paradigm integration, engaging engineers and scientists committed to turning cutting-edge science into real-world impact.
Co-founder and Advisor Rohan Williams, Ph.D., brings deep expertise in multi-omics, genome-resolved metagenomics, and advanced machine learning to guide the analysis of complex biological systems.
Zhao Peng, Ph.D., a scientist with a cellular biology background, excels in simplifying complex scientific concepts into accessible, impactful ideas and leads our internal innovation and bridging discussions focused on commercial applications and uses.
Steering the company is Founder and CEO Damien Keogh, Ph.D., whose biotechnology expertise and molecular microbiology background ensure that scientific breakthroughs are matched with strategic growth, high-profile collaborations, and global partnerships. Together, our team and platform exemplify BluMaiden’s unique ability to bridge natural biological systems with next-generation drug discovery.
Singapore-based operations conducted at Neocytogen’s research collaboration facility under a collaboration agreement and facilities license.
BluMaiden Biosciences Offices and Joint Research Facility
1 Venture Avenue
#01-08 Perennial Business City
Singapore 608521
